読み込み中
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
前日終値
$2.48
+$0.06 · +2.48%
日中の時刻はETです。市場データは遅延する場合があります。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日中レンジ
現在 $2.48
52週レンジ
現在 $2.48
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
45
まちまち
リスク
51
やや高いリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日中レンジ
現在 $2.48
52週レンジ
現在 $2.48
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 6626.7万 USD | 5196.4万 USD | 3031.2万 USD | 2708万 USD | 2373.5万 USD |
| 販売・一般管理 | 1698.4万 USD | 1861.3万 USD | 1268.8万 USD | 1270万 USD | 1313.2万 USD |
| 営業費用 | 8325.1万 USD | 7057.7万 USD | 4300万 USD | 8842.8万 USD | 3686.7万 USD |
| 減価償却費と償却費 | 31.3万 USD | 35.9万 USD | 37.4万 USD | 37.3万 USD | 19.5万 USD |
| 営業利益 | −8325.1万 USD | −7057.7万 USD | −4300万 USD | −8842.8万 USD | −3686.7万 USD |
| 純利益 | −4561.7万 USD | −3618.4万 USD | −1.17億 USD | −8796.6万 USD | −3450.6万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI739.98万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM504.04万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF254.68万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO174.39万0.01%139.72億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO131.58万0.01%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS60.92万0.00%338.69億 USD0.31%$78.35+0.32%
iShares Micro-Cap ETFIWC58.42万0.04%13.17億 USD0.60%$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC27.08万0.03%10.45億 USD0.20%$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
